Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Metastatic Breast Cancer
NCT00025584Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2001
- Primary completion
- Aug 2004
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Objective Tumor Response (CR + PR) up to 24 months. Started Aug 2001; status: completed.
02
Drugs
bortezomib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00025584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025584.